Cargando…

High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry

OBJECTIVE: The aim of this study was to assess the association between high on-aspirin treatment platelet reactivity (HAPR) and the subsequent risk of restenosis after percutaneous coronary intervention (PCI) with predominantly drug-eluting stents. BACKGROUND: The association between HAPR and subseq...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayer, Katharina, Ndrepepa, Gjin, Schroeter, Mira, Emmer, Christopher, Bernlochner, Isabell, Schüpke, Stefanie, Gewalt, Senta, Hilz, Raphaela, Coughlan, John Joseph, Aytekin, Alp, Heyken, Clarissa, Morath, Tanja, Schunkert, Heribert, Laugwitz, Karl-Ludwig, Sibbing, Dirk, Kastrati, Adnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449652/
https://www.ncbi.nlm.nih.gov/pubmed/36786829
http://dx.doi.org/10.1007/s00392-023-02161-z
_version_ 1785095005607559168
author Mayer, Katharina
Ndrepepa, Gjin
Schroeter, Mira
Emmer, Christopher
Bernlochner, Isabell
Schüpke, Stefanie
Gewalt, Senta
Hilz, Raphaela
Coughlan, John Joseph
Aytekin, Alp
Heyken, Clarissa
Morath, Tanja
Schunkert, Heribert
Laugwitz, Karl-Ludwig
Sibbing, Dirk
Kastrati, Adnan
author_facet Mayer, Katharina
Ndrepepa, Gjin
Schroeter, Mira
Emmer, Christopher
Bernlochner, Isabell
Schüpke, Stefanie
Gewalt, Senta
Hilz, Raphaela
Coughlan, John Joseph
Aytekin, Alp
Heyken, Clarissa
Morath, Tanja
Schunkert, Heribert
Laugwitz, Karl-Ludwig
Sibbing, Dirk
Kastrati, Adnan
author_sort Mayer, Katharina
collection PubMed
description OBJECTIVE: The aim of this study was to assess the association between high on-aspirin treatment platelet reactivity (HAPR) and the subsequent risk of restenosis after percutaneous coronary intervention (PCI) with predominantly drug-eluting stents. BACKGROUND: The association between HAPR and subsequent risk of restenosis after PCI is unclear. METHODS: This study included 4839 patients undergoing PCI (02/2007–12/2011) in the setting of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) registry. Platelet function was assessed with impedance aggregometry using the multi-plate analyzer immediately before PCI and after intravenous administration of aspirin (500 mg). The primary outcome was clinical restenosis, defined as target lesion revascularization at 1 year. Secondary outcomes included binary angiographic restenosis and late lumen loss at 6- to 8-month angiography. RESULTS: The upper quintile cut-off of platelet reactivity measurements (191 AU × min) was used to categorize patients into a group with HAPR (platelet reactivity > 191 AU × min; n = 952) and a group without HAPR (platelet reactivity ≤ 191 AU × min; n = 3887). The primary outcome occurred in 94 patients in the HAPR group and 405 patients without HAPR (cumulative incidence, 9.9% and 10.4%; HR = 0.96, 95% CI 0.77–1.19; P = 0.70). Follow-up angiography was performed in 73.2% of patients. There was no difference in binary restenosis (15.2% vs. 14.9%; P = 0.79) or late lumen loss (0.32 ± 0.57 vs. 0.32 ± 0.59 mm; P = 0.93) between patients with HAPR versus those without HAPR. CONCLUSIONS: This study did not find an association between HAPR, measured at the time of PCI, and clinical restenosis at 1 year after PCI. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-10449652
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-104496522023-08-26 High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry Mayer, Katharina Ndrepepa, Gjin Schroeter, Mira Emmer, Christopher Bernlochner, Isabell Schüpke, Stefanie Gewalt, Senta Hilz, Raphaela Coughlan, John Joseph Aytekin, Alp Heyken, Clarissa Morath, Tanja Schunkert, Heribert Laugwitz, Karl-Ludwig Sibbing, Dirk Kastrati, Adnan Clin Res Cardiol Original Paper OBJECTIVE: The aim of this study was to assess the association between high on-aspirin treatment platelet reactivity (HAPR) and the subsequent risk of restenosis after percutaneous coronary intervention (PCI) with predominantly drug-eluting stents. BACKGROUND: The association between HAPR and subsequent risk of restenosis after PCI is unclear. METHODS: This study included 4839 patients undergoing PCI (02/2007–12/2011) in the setting of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) registry. Platelet function was assessed with impedance aggregometry using the multi-plate analyzer immediately before PCI and after intravenous administration of aspirin (500 mg). The primary outcome was clinical restenosis, defined as target lesion revascularization at 1 year. Secondary outcomes included binary angiographic restenosis and late lumen loss at 6- to 8-month angiography. RESULTS: The upper quintile cut-off of platelet reactivity measurements (191 AU × min) was used to categorize patients into a group with HAPR (platelet reactivity > 191 AU × min; n = 952) and a group without HAPR (platelet reactivity ≤ 191 AU × min; n = 3887). The primary outcome occurred in 94 patients in the HAPR group and 405 patients without HAPR (cumulative incidence, 9.9% and 10.4%; HR = 0.96, 95% CI 0.77–1.19; P = 0.70). Follow-up angiography was performed in 73.2% of patients. There was no difference in binary restenosis (15.2% vs. 14.9%; P = 0.79) or late lumen loss (0.32 ± 0.57 vs. 0.32 ± 0.59 mm; P = 0.93) between patients with HAPR versus those without HAPR. CONCLUSIONS: This study did not find an association between HAPR, measured at the time of PCI, and clinical restenosis at 1 year after PCI. GRAPHICAL ABSTRACT: [Image: see text] Springer Berlin Heidelberg 2023-02-14 2023 /pmc/articles/PMC10449652/ /pubmed/36786829 http://dx.doi.org/10.1007/s00392-023-02161-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Mayer, Katharina
Ndrepepa, Gjin
Schroeter, Mira
Emmer, Christopher
Bernlochner, Isabell
Schüpke, Stefanie
Gewalt, Senta
Hilz, Raphaela
Coughlan, John Joseph
Aytekin, Alp
Heyken, Clarissa
Morath, Tanja
Schunkert, Heribert
Laugwitz, Karl-Ludwig
Sibbing, Dirk
Kastrati, Adnan
High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry
title High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry
title_full High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry
title_fullStr High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry
title_full_unstemmed High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry
title_short High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry
title_sort high on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the intracoronary stenting and antithrombotic regimen-aspirin and platelet inhibition (isar-aspi) registry
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449652/
https://www.ncbi.nlm.nih.gov/pubmed/36786829
http://dx.doi.org/10.1007/s00392-023-02161-z
work_keys_str_mv AT mayerkatharina highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry
AT ndrepepagjin highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry
AT schroetermira highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry
AT emmerchristopher highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry
AT bernlochnerisabell highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry
AT schupkestefanie highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry
AT gewaltsenta highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry
AT hilzraphaela highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry
AT coughlanjohnjoseph highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry
AT aytekinalp highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry
AT heykenclarissa highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry
AT morathtanja highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry
AT schunkertheribert highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry
AT laugwitzkarlludwig highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry
AT sibbingdirk highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry
AT kastratiadnan highonaspirintreatmentplateletreactivityandrestenosisafterpercutaneouscoronaryinterventionresultsoftheintracoronarystentingandantithromboticregimenaspirinandplateletinhibitionisaraspiregistry